医学通信公司
期刊
会议
图书
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1546)医学通信公司
摘要:View the Expanded Table: Some Vaccines Recommended for Use in Adults
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1546)医学通信公司
摘要:The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), her...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, ha...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has approved brigatinib (Alunbrig – Takeda), an oral tyrosine kinase inhibitor, for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). Tr...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has granted accelerated approval to copanlisib (Aliqopa – Bayer), an intravenously administered phosphatidylinositol 3-kinase (PI3K) inhibitor, for treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicul...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourt...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has approved deutetrabenazine (Austedo – Teva), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of chorea associated with Huntington's disease and, more recently, for treatment of tardive dyskinesia in adults. It is the second VMAT2 inhibitor to ...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1545)医学通信公司
摘要:The FDA has approved ibalizumab-uiyk (Trogarzo – Theratechnologies/TaiMed), a CD4-directed monoclonal antibody, for IV treatment of multidrug-resistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure on their current regimen. Iba...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1544)医学通信公司
摘要:View the Comparison Table: Some Oral/Topical Opioid Analgesics
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1544)医学通信公司
摘要:Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that i...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×